LPLAT9 is also implicated in IgE over-production in human allergic inflammation, and would be a novel therapeutic target for general allergic diseases, since an epigenome association study has identified LPLAT9 as the least methylated loci associated with high IgE serum concentration (138) (Table 5). Here, LPCAT2 is linked to allergic disease.